About Goldline Pharmaceutical Ltd IPO

We are engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the “Goldline” brand are not manufactured by our Company. Instead, we enter into contractual arrangements with third-party manufacturers, who produce the products based on our market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.The products are marketed and sold exclusively under the “Goldline” brand. Our customers primarily comprise distributors, who further supply to retailers and wholesalers, forming the main channel of distribution to the end-users. Presently, we maintain contractual arrangements with 15 manufacturers and 7 distributors, ensuring a stable supply chain and consistent market presence.Our Company also extend comprehensive material supply and procurement support to hospitals and healthcare partners. Through our promoter group entities as Numerius Healthcare Pvt Ltd (Formerly Known As Enrich Healthcare & PSPL International) & Activista Healthcare Pvt Ltd (Formerly Known As Gold N Gold Distributors). Our Company manage trading and supply chain operations, thereby ensuring reliable procurement, seamless distribution, and logistical efficiency.Our Promoters, Mr. Amol Laxmikant Mujumdar and Mr. Swapan Premprakash Khandelwal, with 25 years and 30 years of experience respectively in pharmaceutical marketing and supply chain management, have been instrumental in shaping the growth and strategic direction of the Company. Their expertise continues to drive our business expansion and operational resilience.

Goldline Pharmaceutical IPO Subscription Breakdown

Investory CategorySubscription PercentageAmount Raised (₹ Crores)
Qualified Institutional Buyers (QIBs)50%1350000 crores
Non-Institutional Investors (NIIs15%405000 crores
Retail Individual Investors (RIIs)35%945000 crores

Goldline Pharmaceutical IPO Financial Highlights

Goldline Pharmaceutical Ltd’s total income 0 by 0.00% and total expenses 0 by 0.00%, resulting in an EBITDA 5.83 by 35.58% and a profit after tax (PAT) 0 by 0.00% between March 31, 2025 and March 31, 2026.

Amount in Crores
2.1931 March 2026
4.331 March 2025
5.8331 March 2024

5.83

5

5

4

3

3

2

2

1

1

0

EBITDA

Goldline Pharmaceutical IPO Strengths & Weaknesses

  • Experienced promoters and management team.

  • Asset-light business model through third-party manufacturing.

  • Diversified pharma product portfolio across multiple therapeutic categories.

  • Scalable distribution-led business model.

  • Established supplier and distributor relationships.

  • Presence across multiple Indian states.

Goldline Pharmaceutical IPO Important Dates & Issue Details

Allotment DateListing Date
15 May '2619 May '26

Goldline Pharmaceutical IPO Lot Size and Investment Details

Minimum Lot Size3000 shares
Maximum Lot Size (Retail)9000 shares

The lot size of Goldline Pharmaceutical Ltd ipo has been designed to ensure broad participation while maintaining optimal price discovery.

How to Apply for Goldline Pharmaceutical IPO

  1. Log in to your Choice account
  2. Select IPO
  3. Enter the number of lots and your price
  4. Verify UPI ID
  5. Complete the transaction on your UPI app

Contact & Registrar Details

Contact Details

Address

Address

103 F-1 Leela Apartment Shilpa Hsg Society Nagpur

Phone Number

Phone Number

+91 712-278 6666

Registrar Details

Address

Registrar Name

Bigshare Services Pvt.Ltd.

Phone Number

Phone Number

+91 22-6263 8200

Goldline Pharmaceutical IPO FAQs

The minimum lot size is 3000 shares with a price band of ₹41 to ₹43 per share, requiring a minimum investment of ₹2,58,000.

Check allotment status on the registrar's website using PAN number or application number after the Goldline Pharmaceutical Ltd ipo allotment date.

The listing date of Goldline Pharmaceutical Ltd ipo is scheduled for 19 May '26 on NSE/BSE .

Investment decisions should be based on your risk appetite, financial goals, and a thorough analysis of the company's fundamentals and growth prospects.

Consider factors like company fundamentals, valuation, market conditions, and your investment portfolio before making any investment decision.

You can Goldline Pharmaceutical Ltd ipo apply online through your broker's trading platform, mobile app, or through the ASBA facility via internet banking.

The Goldline Pharmaceutical Ltd ipo allotment date and listing date are 15 May '26and 19 May '26, respectively.

Yes, you can apply through your bank's internet banking portal. The funds will remain in your account until allotment, and no need for separate IPO funding.